Genmab — Marts 2018

[bibob]

God morgen.

[E_L]

I hope we can see some data from this Dara-CyBorD study soon; Primary Completion Date was just set to March 8, 2018. Everything that was recruiting now set to Active, not recruiting . https://clinicaltrials.gov/ct2/show/study/NCT02951819?term=daratumumab+OR+ofatumumab+OR+tisotumab&lupd_s=03%2F13%2F2018&rank=1#locn

[E_L]

March 15, 2018 is Late-Breaking Data Submission Deadline for ASCO. Coincidence?

[Raketten50]

Jeg faldt over denne interessante analyse fra i går:: https://simplywall.st/stocks/dk/pharmaceuticals-biotech/cph-gen/genmab-shares/news/stocks-take-a-hit-how-will-genmab-a-s-cphgen-fare/ , og forfatteren er åbenbart ikke en hr-hvem-som-helst https://en.m.wikipedia.org/wiki/Daniel_S._Loeb

[E_L]

lol, i really hope you meant that as a joke Raketten

[peter12]

(simplywall.st)

[Raketten50]

Ups - det var en smutter. Sorry

[Mcjean]

I always buy perfume, i just love the smell of stock i love, especially Genmab, sry but i'm obviously not a pro......sry Benjamin Graham but your statement sucks!..... in my brain at least!

[Raffles]

I eftermiddag er der "Online publication of Abstracts" til AACR (afholdes 14-18 april i Chicago). Er der en mikroskopisk chance for at GEN/JnJ har abstracts med, f.eks Dara + Tecentriq i NSCLC??

[Solsen]

Nej

[Solsen]

Ikke iflg Winkel

[Solsen]

BMS data er vel eneste chance.

[Legolas23]

Dara + Tecentriq er Q2 hvilket betyder omkring sommer, som jeg har forstået...

[Legolas23]

https://medwatch.dk/secure/Medicinal___Biotek/article10411298.ece?utm_campaign=Middag&utm_content=2018-03-14 12%3A15%3A59&utm_medium=top&utm_source=Feed

[DevOp]

Dara + Tecentriq H2, Estimated Primary Completion Date: July 25, 2018. https://clinicaltrials.gov/ct2/show/NCT03023423

[E_L]

interesting remark from JNJ on how they expect BCMA and anti-38 are going to co-exist in that link from peter12 yesterday 23:18

[E_L]

I can't remember who posted that JNJ increased price for Dara recently; did we have a link for that?

[Teller]

Are we running into a golden cross here?

[bibob]

Dette er da rabatter der er til at forstå. Godt og vel prisen på Genmab. https://medwatch.dk/Medicinal___Biotek/article10402951.ece

[E_L]

Yes, it is an industry wide trend, JNJ saying "However, Duato said the company wasn't concerned about this, because J&J's strategy is to grow through volume rather than price increases" https://www.foxbusiness.com/markets/forget-remicade-heres-how-johnson-johnson-plans-to-grow